

CORTEX PHARMACEUTICALS INC/DE/  
Form SC 13D  
October 31, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**Cortex Pharmaceuticals, Inc.**

(Name of Issuer)

Common Stock, \$0.001 par value  
(Title of Class of Securities)

220524300;  
(CUSIP Number)

Sung Youp Lee

158-24 Dongsung B/D 3F. Samsung-Dong. Gangnam-Gu. Seoul. Korea

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form SC 13D

**+82 2 784 9961**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**October 20, 2011**

**(Dates of Event Which Requires Filing of this Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.  x

CUSIP No. **220524300**

(1) Name of reporting person

**Samyang Optics Co., Ltd.**

(2) Check the appropriate box if a member of a group

(a)  (b)

(3) SEC use only

(4) Source of funds (see instructions)

**WC**

(5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

(6) Citizenship or place of organization

**South Korea**

(7) Sole voting power

Number of

shares **14,257,666 (1)**  
(8) Shared voting power

beneficially

owned by **8,456,833 (2)**  
each (9) Sole dispositive power

reporting

person **14,257,666 (1)**  
(10) Shared dispositive power

with:

**8,456,833 (2)**

(11) Aggregate amount beneficially owned by each reporting person

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form SC 13D

22,714,499

(12) Check if the aggregate amount in Row (11) excludes certain shares ..

(13) Percent of class represented by amount in Row (11)

24.85% (3)

(14) Type of reporting person

CO

- (1) Consists of (i) 10,176,033 shares of Cortex Pharmaceuticals, Inc. common stock, and (ii) a warrant to purchase up to 4,081,633 shares of common stock at an exercise price of \$0.206 per share.
- (2) Consists of (i) 6,765,466 shares of Cortex Pharmaceuticals, Inc. common stock, and (ii) a warrant to purchase up to 1,691,367 shares of common stock at an exercise price of \$0.1035 per share.
- (3) Based on 78,858,197 shares of common stock outstanding as reported in Cortex Pharmaceuticals, Inc. s Quarterly Report on Form 10-Q filed Aug 18, 2011.

CUSIP No.

(1) Name of reporting person

Samyang Value Partners Co., Ltd.

(2) Check the appropriate box if a member of a group

(a)  (b)

(3) SEC use only

(4) Source of funds (see instructions)

WC

(5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

(6) Citizenship or place of organization

South Korea

(7) Sole voting power

Number of

shares  0 (8) Shared voting power

beneficially

owned by  8,456,833 (1)  
each (9) Sole dispositive power

reporting

person  0 (10) Shared dispositive power

with:

8,456,833 (1)

(11) Aggregate amount beneficially owned by each reporting person

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form SC 13D

8,456,833 (1)

(12) Check if the aggregate amount in Row (11) excludes certain shares "

(13) Percent of class represented by amount in Row (11)

9.69% (2)

(14) Type of reporting person

CO

- (1) Consists of (i) 6,765,466 shares of Cortex Pharmaceuticals, Inc. common stock, and (ii) a warrant to purchase up to 1,691,367 shares of common stock at an exercise price of \$0.1035 per share
- (2) Based on 78,858,197 shares of common stock outstanding as reported in Cortex Pharmaceuticals, Inc. s Quarterly Report on Form 10-Q filed Aug 18, 2011.

**Item 1. Security and Issuer**

The class of equity securities to which this Schedule 13D (this Schedule 13D ) relates is the common stock( par value \$0.001 per share (the Shares )) and warrant (no par value), of *Cortex Pharmaceuticals, Inc.*, a Irvine corporation ( Company ). The principal executive offices of Issuer are located at *15241 Barranca Parkway Irvine, California 92618*

**Item 2. Identity and Background**

This Schedule 13D is being jointly filed by Samyang Value Partners Co., Ltd. ( Purchaser ), a South Korea corporation and a wholly-owned subsidiary of Samyang Optics Co., Ltd. ( Parent ), a South Korea corporation, and Parent.

Parent s principal executive offices are located at 654-4, BONGAM-DONG, MASANHOIWON-GU, CHANGWON-SI, KYOUNGSANGNAM-DO, SOUTH KOREA. The telephone number of Parent is 82-2-784-9961. Parent is a global manufacturer of Optical Lens mainly for CCTV and CAMERA. Parent has been manufacturing Interchangeable DSLR Camera Lens, based on the knowledge and the experiences it have learned since 1970's, also manufacturing CCTV lens. As uncertainties arise with increasing frequency in modern society, more and more people are seeking security, so the demand for CCTV and its lens is increasing.

Purchaser s principal executive offices are located 158-12 SEOYOUNG B/D 12F SAMSUNG-DONG GANGNAM-GU SEOUL KOREA. The telephone number of Purchaser is 82-2-6005-8700. Purchaser is a wholly-owned subsidiary of Parent. Purchaser s business purpose is management consulting, investment and investment consulting.

Parent and Purchaser are collectively hereinafter referred to as the Reporting Persons.

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13D as Exhibit 1.

The name, business address, present principal occupation or employment and citizenship of each director and executive officer of each of Purchaser and Parent is set forth on Schedule A. During the preceding five years, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, any of the persons listed on Schedule A, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

**Item 3. Source and Amount of Funds**

On January 15, 2010, Parent acquired Convertible Note( Note ) in cash for an aggregate purchase price of \$1,500,000 pursuant to Securities Purchase Agreement entered into with the Company. On June 7, 2010, Parent elected to convert Note into 10,445,579 shares of Common Stock and 4,081,633 shares of Warrant to purchase Common Stock, and conversion price is approximately \$0.147 and exercise price for warrant is \$0.206.

On October 20, 2011, Purchaser entered into Securities Purchase Agreement with the Company. Pursuant to Securities Purchase Agreement, the Company agreed to sell to Samyang Value Partners an aggregate of 6,765,466 shares of Common Stock (the Shares ) at a price of \$0.0739 per share and 1,691,367 shares of Warrant to purchase Common Stock in cash for an aggregate purchase price of \$500,000.

**Item 4. Purpose of the Transaction**

The Reporting Persons acquired the shares of Common Stock for investment purposes, and the Reporting Persons intend to evaluate the performance of such securities as an investment in the ordinary course of business. The Reporting Persons pursue an investment objective of long-term capital appreciation. In pursuing this investment objective, the Reporting Persons analyze the management, operations and markets of companies in which they invest, including the Company, on a continual basis through analysis of research and discussions with industry and market observers and with representatives of such companies.

Each Reporting Person that owns shares of Common Stock assesses the Company's business, financial condition, and results of operations as well as economic conditions and securities markets in general and those for the Company's shares in particular. Depending on such assessments, one or all of such Reporting Persons may acquire additional shares or may sell or otherwise dispose of all or some of the shares of Common Stock. Such actions will depend on a variety of factors, including current and anticipated trading prices for Common Stock, alternative investment opportunities, and general economic, financial market and industry conditions.

Except as described in this Item 4, none of the Reporting Persons has any plans or proposals that relate to, or would result in, any matter required to be disclosed in response to paragraphs as follows

- (a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer;
- (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries;
- (c) A sale or transfer of a material amount of assets of the issuer or any of its subsidiaries;
- (d) Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;
- (e) Any material change in the present capitalization or dividend policy of the issuer;
- (f) Any other material change in the issuer's business or corporate structure including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940;
- (g) Changes in the issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;
- (h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;
- (i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or
- (j) Any action similar to any of those enumerated above.

**Item 5. Interest in Securities of Issuer**

**(a)**

For purposes of calculating the percentages set forth in this Item 5, the number of shares of Common Stock outstanding was assumed to be 85,623,663 consisting of 78,858,197 shares outstanding as reported by the Company in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 plus 6,765,466 shares of Common Stock acquired by Purchaser on October 20, 2011

Parent currently holds 14,257,666 shares representing 15.89% (based on shares of Common Stock outstanding) consisting of 10,176,033 shares of Common Stock and 4,081,633 shares of Warrant to purchase Common Stock.

Purchase currently holds 8,456,833 shares representing 9.69% (based on shares of Common Stock outstanding) consisting of 6,765,466 shares of Common Stock and 1,691,367 shares of Warrant to purchase Common Stock.



Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form SC 13D

Consequently, all the shares that each reporting person has are 22,714,499 representing 24.85% based on shares of Common Stock outstanding

**(b)**

As a result of share ownership as set forth in Item 3 of this Schedule 13D, Parent may be deemed to be the beneficial owner of 14,257,666 Shares, over which it has the sole power to vote and the sole power to dispose. Accordingly, Parent may be deemed to be the beneficial owner of 8,456,833 Shares, over which it has the Shared power to vote and the Shared power to dispose, and all Shares that may be deemed to be beneficially owned by Parent constitute approximately 24.85% based on shares of Common Stock outstanding. Also, purchaser may be deemed to be the beneficial owner of 8,456,833 Shares, over which it has the shared power to vote and the shared power to dispose, and all Shares that may be deemed to be beneficially owned by Purchaser constitute approximately 9.69% based on shares of Common Stock outstanding.

**(c)**

Except as disclosed in this Schedule 13D, to the knowledge of the Reporting Persons, no transactions in the class of securities reported have been effected during the past 60 days by any person named in Schedule A or Item 5(a).

**(d)**

To the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities of Issuer reported herein.

**(e)**

Not applicable.

**Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of Issuer**

Except as disclosed in this Schedule 13D, to the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise), among the Reporting Persons or, to the knowledge of any of the Reporting Persons, any other person or entity referred to in Item 2 (including those listed on Schedule A), or between such persons and any other person, with respect to any securities of Issuer, including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

**Item 7. Material to be Filed as Exhibits**

Exhibit 1 Joint Filing Agreement, dated October 31, 2011, among the Reporting Persons.

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 13D is true, complete and correct.

Date: October 31, 2011

**SAMYANG OPTICS CO., LTD.**

By: /s/ Dong Hoon Kim  
Name: Dong Hoon Kim  
Title: Director

**SAMYANG VALUE PARTNERS CO., LTD.**

By: /s/ Hyoung Rae Cho  
Name: Hyoung Rae Cho  
Title: Director

---

**SCHEDULE A**

## CERTAIN INFORMATION CONCERNING DIRECTORS AND EXECUTIVE OFFICERS OF SAMYNAG

## OPTICS CO., LTD. AND SAMYANG VALUE PARTNERS CO., LTD.

1. *Directors and Executive Officers of Parent.* The following table sets forth the name and present principal occupation or employment for each director and executive officer of Parent. The current business address of each such person is 654-4 Bongamdong, Masanhoiwongu, Changwonsi, South Korea. Each such person is a citizen of Republic of Korea.

<b>Name</b>	<b>Present Principal Occupation or Employment</b>
Soung Jin Kim	Director
Dong Hoon Kim	Director
Bum Suk Ko	Director
Boung Gil Kim	Director
Yeon Il Hwang	Director
Jong Bok Lee	Director
Jung Il Kim	Auditor

2. *Directors and Executive Officers of Purchaser.* The following table sets forth the name and present principal occupation or employment for each director and executive officer of Purchaser. The current business address of each such person is 158-12 SEOYOUNG B/D 12F SAMSUNG-DONG GANGNAM-GU SEOUL SOUTH KOREA. Each such person is a citizen of Republic of Korea.

<b>Name</b>	<b>Present Principal Occupation or Employment</b>
Hae Don You	Director
Hyoung Rae Cho	Director
Soon Hee Joo	Auditor